MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Todays Market
- Indian Stock Market Updates June 21, 2019
ALEMBIC PHARMA Surges by 6%; BSE HEALTHCARE Index Down 0.6%
Fri, 21 Jun 09:24 AM
ALEMBIC PHARMA share price has zoomed 6% and is presently trading at Rs 488.
Meanwhile, the BSE HEALTHCARE Index is at 12,797 (down 0.6%).
Among the top Gainers in the BSE HEALTHCARE Index today is ALEMBIC PHARMA (up 5.8%).
FORTIS HEALTHCARE (down 0.1%) and GLENMARK PHARMA (down 0.2%) are among the top losers today.
Over the last one year, ALEMBIC PHARMA has moved down from Rs 516 to Rs 488, registering a loss of Rs 28 (down 5.5%).
On the other hand, the BSE HEALTHCARE has moved down from 14,272 to 12,797, loss of 1,475 points (down 10.9%) during the last 12 months.
The top gainers among the BSE HEALTHCARE Index stocks during this same period were MERCK (up 52.4%), DIVIS LABORATORIES (up 46.1%) and J.B.CHEMICALS (up 40.4%).
What About the Benchmark Indices?
The BSE Sensex is at 39,618 (down 0.5%).
The top gainers among the BSE Sensex stocks today are HCL TECHNOLOGIES (up 0.5%), ONGC (up 0.3%) and NTPC (up 0.3%). Other gainers include HUL (up 0.1%) and COAL INDIA . The most traded stocks in the BSE Sensex are ONGC and NTPC.
In the meantime, NSE Nifty is at 11,828 (down 0.4%). UPL (up 2.4%) is among the top gainers in NSE Nifty.
Over the last 12 months, the BSE Sensex has moved up from 35,547 to 39,618, registering a gain of 4,071 points (up 10.9%).
ALEMBIC PHARMA Financial Update...
ALEMBIC PHARMA net profit down at Rs 1 billion for the quarter ended March 2019, compared to a loss of Rs 2 billion a year ago. Net Sales declined 9.0% to Rs 9.3 billion during the period as against Rs 10.2 billion in January-March 2018.
For the year ended March 2019, ALEMBIC PHARMA reported 40.8% increase in net profit to Rs 5.9 billion compared to net profit of Rs 4.2 billion during FY18.
Revenue of the company grew 25.7% to Rs 39 billion during FY19.
The current Price to earnings ratio of ALEMBIC PHARMA, based on rolling 12 month earnings, stands at 15.5x.
Indian Share Market Update: Top Gainers and Losers
|
| |
Stock Market Updates
NBFCs in Focus, Rising Crude Oil Prices and Top Stocks in Action Today (Today's Market)
Aug 20, 2019 Pre-OpenOn Monday, Indian share markets witnessed selling pressure during closing hours and ended marginally higher. The BSE Sensex closed higher by 52 points to end the day at 37,402.
View More Indian Share Market NewsMost Popular
My Top 3 Dividend Millionaire Stocks(Profit Hunter)
Aug 7, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)
Aug 8, 2019This debt-free, well-managed company is all set to soar.
This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)
Aug 12, 2019My experience at the recent AGM of this smallcap company which has financials of any FMCG major.
Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)
Aug 9, 2019Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.
Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)
Aug 12, 2019Only These Smallcaps Will Give Historic Returns in the Future.
More|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Surges by 6%; BSE HEALTHCARE Index Down 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!